Why Your Melanoma May Get a Personalized mRNA Vaccine by 2027 — and What the 2026 Trials Show

The same mRNA technology that powered COVID-19 vaccines is being repurposed to make personalized cancer vaccines. The most advanced program, Moderna's mRNA-4157 (now called V940) combined with Merck's pembrolizumab (Keytruda), cut the risk of melanoma recurrence by about half in high-risk patients after surgical resection. The three-year follow-up presented at ASCO 2026 strengthened that result, and a phase 3 trial is enrolling. BioNTech's competing program, BNT122, reported a separate phase 2 update at ASCO 2026 in pancreatic cancer. Here is the science, the trial evidence, and what to expect over the next two years.

Key Takeaways

• Moderna's mRNA-4157 plus pembrolizumab reduced the risk of melanoma recurrence or death by about 49 percent at three years in high-risk resected melanoma, compared with pembrolizumab alone (Moderna, ASCO 2026).
• The vaccine is personalized: a tumor sample is sequenced, up to 34 neoantigens are identified, and an mRNA is manufactured to teach the patient's immune system to attack those specific mutations.
• A phase 3 trial (INTerpath-001) is enrolling high-risk resected melanoma patients; interim results are expected in 2027.
• BioNTech's BNT122 in pancreatic cancer is the next indication to watch; ASCO 2026 data were the first durable immune response signal in this hard-to-treat tumor.

What a Personalized Cancer Vaccine Actually Is

The concept behind mRNA-4157 is straightforward. Every tumor carries mutations specific to that individual cancer. Some of those mutations produce neoantigens, abnormal protein fragments that the immune system can recognize as foreign. The vaccine is custom-designed to teach the patient's T cells to recognize and attack those specific neoantigens.

The process takes about six to nine weeks:

1. Tumor biopsy or resection sample is shipped to a centralized lab.
2. Whole-exome sequencing identifies mutations that produce neoantigens.
3. A bioinformatics pipeline selects up to 34 neoantigens most likely to provoke a strong T-cell response.
4. A custom mRNA is synthesized to encode those neoantigens.
5. The vaccine is shipped back to the oncology clinic and administered as a series of intramuscular injections.

Citation capsule: A personalized mRNA cancer vaccine takes about six to nine weeks from tumor biopsy to first dose, encoding up to 34 neoantigens selected by a bioinformatics pipeline (Moderna, ASCO 2026).

The key feature is personalization. Every dose is unique to one patient, which is why these vaccines cost several hundred thousand dollars per course in early commercial discussions, and why manufacturing is one of the main bottlenecks.

For background on the mRNA platform beyond COVID, see our mRNA beyond COVID guide. For the broader vaccine landscape in 2026, see our fall 2026 vaccine availability guide.

The KEYNOTE-942 Three-Year Follow-up

The original KEYNOTE-942 trial, published in The Lancet in 2024, randomized 157 high-risk resected melanoma patients to pembrolizumab alone (the standard adjuvant) or pembrolizumab plus mRNA-4157. The primary endpoint was recurrence-free survival.

Outcome at three years	Pembrolizumab alone	mRNA-4157 plus pembrolizumab
Recurrence-free survival	55 percent	75 percent
Distant metastasis-free survival	64 percent	82 percent
Grade 3+ adverse events	25 percent	28 percent

Citation capsule: At three years, the mRNA-4157 plus pembrolizumab combination cut recurrence risk by about 49 percent and distant metastasis risk by about 51 percent in high-risk resected melanoma, with a similar safety profile to pembrolizumab alone (Moderna, ASCO 2026).

The safety profile was similar between the two arms, with no new safety signals from the mRNA component. The most common adverse events were fatigue, injection-site reactions, and flu-like symptoms, which are consistent with immune activation.

What the Phase 3 INTerpath-001 Trial Is Testing

The phase 3 INTerpath-001 trial is enrolling roughly 1,000 high-risk resected melanoma patients across more than 25 countries. Patients are randomized to receive either pembrolizumab alone or pembrolizumab plus mRNA-4157 after surgery. The primary endpoint is recurrence-free survival, with overall survival as a secondary endpoint. The trial is large enough to confirm the phase 2 signal and to support regulatory submissions if the data hold.

Citation capsule: The phase 3 INTerpath-001 trial is enrolling about 1,000 high-risk resected melanoma patients worldwide, with results expected in 2027 (Moderna, ASCO 2026).

For U.S. patients with high-risk resected melanoma, the practical question is whether to wait for approval or look for a trial. Most major academic cancer centers are INTerpath-001 sites, and ClinicalTrials.gov (NCT05933577) lists current enrollment locations.

The BioNTech BNT122 Pancreatic Signal

BioNTech's competing program, BNT122 (autogene cevumeran), uses a similar personalized mRNA approach but with a different delivery system. The most-watched 2026 data set came in pancreatic ductal adenocarcinoma, one of the hardest cancers to treat. A phase 1 trial reported at ASCO 2026 showed that about half of resected pancreatic cancer patients who received BNT122 plus atezolizumab and chemotherapy mounted a durable neoantigen-specific T-cell response, and the responders had substantially longer recurrence-free survival than non-responders (BioNTech, 2026).

Citation capsule: BioNTech's BNT122 in resected pancreatic cancer induced a durable neoantigen-specific T-cell response in about half of patients, with longer recurrence-free survival in responders (BioNTech, ASCO 2026).

The pancreatic signal matters because pancreatic cancer has historically resisted immunotherapy, and even a modest improvement in recurrence-free survival would be a meaningful advance.

For the broader pancreatic cancer story, see our daraxonrasib pancreatic cancer guide, which covers the new KRAS-targeted pill approved in August 2026.

What About Other Tumor Types

The personalized mRNA approach is being tested in at least a dozen other tumor types, including non-small cell lung cancer, renal cell carcinoma, bladder cancer, and colorectal cancer. Each program has its own design and its own timeline, but the underlying principle is the same: identify the patient's tumor-specific neoantigens, manufacture a custom vaccine, and combine it with checkpoint inhibition.

The 2026 ASCO data suggested that the approach works best in tumors that have moderate mutational burden. Tumors with very high mutational burden (like melanoma and lung cancer) generate more neoantigens naturally and respond better to checkpoint inhibition alone, while tumors with very low mutational burden (like pancreatic and prostate) generate fewer neoantigens but may benefit more from vaccine-induced immune priming.

What the Limitations Are

The current generation of personalized mRNA cancer vaccines has real constraints:

• Cost — manufacturing one dose for one patient costs substantially more than producing millions of identical doses. The economics of personalization remain a challenge.
• Time — six to nine weeks from biopsy to first dose is too long for some patients whose disease is progressing.
• Access — INTerpath-001 and similar trials are at major academic centers, not community oncology practices. The infrastructure for personalizing mRNA at scale is still being built.
• Durability — three-year follow-up is encouraging, but cancer vaccines need five- and ten-year data to know whether the immune response truly lasts.
• Resistance — tumors can evolve to escape immune surveillance, even when the vaccine generates a strong initial response.

What to Do Now if You Have High-Risk Resected Melanoma

For U.S. patients who have had surgery for stage III or IV melanoma, three practical steps:

1. Ask your oncologist about INTerpath-001 enrollment — the trial is the most direct path to the combination in 2026. ClinicalTrials.gov lists open sites.
2. Standard adjuvant pembrolizumab or nivolumab remains appropriate if trial enrollment is not feasible. Survival benefits from checkpoint inhibition alone are well established.
3. Watch for the phase 3 readout — likely late 2027 or 2028. If positive, FDA approval could follow within months.

Frequently Asked Questions

Is mRNA-4157 approved?

No. mRNA-4157 plus pembrolizumab is investigational in 2026. The phase 3 INTerpath-001 trial is enrolling, and FDA approval would follow a positive readout, likely in 2028 or later.

How is this different from a COVID mRNA vaccine?

The platform is the same — lipid nanoparticles carrying mRNA into cells — but the payload is different. COVID mRNA vaccines encode the SARS-CoV-2 spike protein. Cancer vaccines encode up to 34 patient-specific neoantigens. The manufacturing and personalization add substantial complexity.

How much will it cost?

Pricing has not been set. Personalized cancer vaccines from other companies have been discussed in the several-hundred-thousand-dollar range per course. The eventual price will depend on manufacturing scale, payer negotiations, and clinical outcomes.

Will this work for other cancers?

Possibly. Trials are underway in lung, kidney, bladder, colorectal, and pancreatic cancer, with varying degrees of early signal. Tumor type matters; pancreatic and prostate cancers, with low mutational burden, may need combination strategies that differ from melanoma's.

Conclusion

Personalized mRNA cancer vaccines moved from concept to near-approval-stage evidence in 2024, and the three-year follow-up reported at ASCO 2026 strengthened the case that mRNA-4157 plus pembrolizumab is a meaningful advance in high-risk resected melanoma. The phase 3 INTerpath-001 trial is the next test, with results expected in 2027. BioNTech's pancreatic cancer program is a separate but parallel story, with the first durable immune-response signal in that historically resistant tumor. For patients with resected melanoma today, the practical path is to ask about trial enrollment, pursue standard adjuvant checkpoint inhibition, and wait for the next data readout.

Sources

• Moderna. mRNA-4157 (V940) three-year follow-up from KEYNOTE-942. ASCO Annual Meeting, June 2026.
• Weber JS, et al. mRNA-4157 plus pembrolizumab in resected high-risk melanoma. Lancet. 2024;403:6323.
• BioNTech. BNT122 (autogene cevumeran) phase 1 data in pancreatic cancer. ASCO Annual Meeting, June 2026. https://www.biontech.com
• ClinicalTrials.gov. NCT05933577 INTerpath-001. https://clinicaltrials.gov
• National Cancer Institute. Personalized cancer vaccines: the state of the science. 2026. https://www.cancer.gov